Patent: Methods of Treating FGF21-Associated Disorders

Author(s)

Brian R. Boettcher, Novartis Institutes for BioMedical Research
Shari L. Caplan, Novartis Institutes for BioMedical Research
Douglas S. Daniels, University of DaytonFollow
Bernhard Hubert Geierstanger, Novartis Institute for Functional Genomics
Norio Hamamatsu, Novartis Institutes for BioMedical Research
Stuart Licht
Andreas Loew, Novartis Institutes for BioMedical Research
Stephen Craig Weldon, Novartis Institutes for BioMedical Research

Document Type

Article

Publication Date

5-24-2012

Publication Source

U.S. Patent and Trademark Office

Abstract

The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, includ ing metabolic conditions.

Comments

Pub. No.: US 2012/0129766A1

eCommons Citation

Boettcher, Brian R.; Caplan, Shari L.; Daniels, Douglas S.; Geierstanger, Bernhard Hubert; Hamamatsu, Norio; Licht, Stuart; Loew, Andreas; and Weldon, Stephen Craig, "Patent: Methods of Treating FGF21-Associated Disorders" (2012). Chemistry Faculty Publications. 101.
https://ecommons.udayton.edu/chm_fac_pub/101